Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
Fluoroquinolone AntibioticsOphthalmological Anti-infectives
Ophthalmic fluoroquinolone antibioticIndicated for bacterial conjunctivitisMinimal systemic absorption
Gatifloxacin/Zymaxid Ophthalmic Sol: 0.5%
On day 1, instill 1 drop in each affected eye every 2 hours while awake, up to 8 times daily. On days 2 to 7, instill 1 drop in each affected eye 2 to 4 times daily while awake.
On days 1 and 2, instill 1 drop in each affected eye every 2 hours while awake, up to 8 times daily. On days 3 to 7, instill 1 drop in each affected eye up to 4 times daily while awake.
1 drop to the affected eye(s) every 5 to 15 minutes for 5 doses within 1 hour before the start of the procedure. Perioperative antisepsis with povidone-iodine is recommended. Subconjunctival or intracameral antibiotics at the end of the procedure is optional. The necessity of continuing topical antimicrobials postoperatively has not been established.
†Indicates off-label use
8 drops/day in affected eye(s).
8 drops/day in affected eye(s) of 0.3% solution only.
No dosage adjustments are needed.
Apply topically to the eye. For topical ophthalmic use only.Instruct patient on proper instillation of eye solution.Avoid contamination of the eye solution; do not to touch the tip of the eye dropper to the eye, fingertips, or other surface.
Tequin:- Store at 77 degrees F; excursions permitted to 59-86 degrees FZymar:- Protect from freezing- Store between 59 to 77 degrees FZymaxid :- Protect from freezing- Store between 59 to 77 degrees F
Gatifloxacin is for topical ophthalmic use only. Corneal endothelial cell injury may occur if gatifloxacin ophthalmic solution is introduced directly into the chamber of the eye.
Prolonged use of gatifloxacin ophthalmic preparations may result in overgrowth of nonsusceptible organisms. If superinfection, including fungal infection, occurs with gatifloxacin use, discontinue therapy and institute an alternative.
Gatifloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to gatifloxacin, a history of quinolone hypersensitivity, or hypersensitivity to any components of the medication. Serious hypersensitivity reactions, including anaphylactoid reactions, angioedema (including pharyngeal, laryngeal, or facial edema), and dyspnea, have been reported with ophthalmic gatifloxacin, even following a single dose. Gatifloxacin should be discontinued if an allergic reaction or any other sign of hypersensitivity appears.
There are no data available on gatifloxacin ophthalmic use in pregnancy to inform a drug-associated risk. However, animal data have shown that administration of oral gatifloxacin throughout organogenesis and during late gestation through lactation did not produce adverse maternal, fetal, or neonatal effects at clinically relevant doses.
There are no data available regarding the presence of gatifloxacin in human milk, the effect of gatifloxacin on breast-feeding infants, or the effect of gatifloxacin on milk production. Animal data have shown that gatifloxacin is excreted in breast milk following oral administration; however, systemic levels of gatifloxacin following topical ocular administration are low and it is unknown whether gatifloxacin would be present in maternal milk at measurable levels following topical ocular administration. Two other fluoroquinolones, ciprofloxacin and ofloxacin, are considered to be compatible with breast-feeding by the American Academy of Pediatrics. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition prior to using ophthalmic gatifloxacin.
keratitis / Delayed / 5.0-10.0ocular hemorrhage / Delayed / 1.0-4.0visual impairment / Early / 1.0-4.0Stevens-Johnson syndrome / Delayed / 0-1.0anaphylactoid reactions / Rapid / Incidence not knownlaryngeal edema / Rapid / Incidence not knownangioedema / Rapid / Incidence not known
conjunctivitis / Delayed / 5.0-10.0dyspnea / Early / Incidence not knownblurred vision / Early / Incidence not knownblepharitis / Early / Incidence not knowncorneal edema / Early / Incidence not known
lacrimation / Early / 5.0-10.0ocular irritation / Rapid / 5.0-10.0ocular discharge / Delayed / 1.0-4.0ocular pain / Early / 1.0-4.0xerophthalmia / Early / 1.0-4.0dysgeusia / Early / 1.0pruritus / Rapid / Incidence not knownrash / Early / Incidence not knownurticaria / Rapid / Incidence not knownocular pruritus / Rapid / Incidence not knownheadache / Early / Incidence not knownnausea / Early / Incidence not known
There are no drug interactions associated with Gatifloxacin products.
Gatifloxacin is bactericidal via inhibition of DNA gyrase (topoisomerase II), an enzyme responsible for counteracting the excessive supercoiling of DNA during replication or transcription and topoisomerase IV, an enzyme that helps separate the daughter DNA molecules. In gram-negative bacteria, the primary target is the DNA gyrase A subunit, while the primary target in gram-positive bacteria is generally topoisomerase IV.
Gatifloxacin is administered topically to the eye. Systemic absorption is minimal.
Ophthalmic RouteFollowing ophthalmic administration, serum concentrations of gatifloxacin are below detectable limits.